Cocrystal Pharma, Inc. · NASDAQ:COCP

Cocrystal Pharma — 2026 International Society For Antiviral Research (ICAR 2026)

17 slides from Cocrystal Pharma's conference presentation, Apr 30, 2026

  1. Slide 1: First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment

    First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results 2026 International Society For Antiviral Research April 30, 2026 Sam Lee, PhD President and co-CEO slee@cocrystalpharma.com

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our development pipeline; our technology platform’s ability to produce viable drug candidates at reduced development timelines and co

  3. Slide 3: The Hidden $60 Billion Norovirus Burden

    The Hidden $60 Billion Norovirus Burden Significant unmet need of Norovirus as a leading cause of acute gastroenteritis across all age groups and regions. 700M 200K 7 700M 200,000 Infections Infections Deaths GII.4 Worldwide Deaths Pandemic Worldwide Worldwide Annually Annually Annually Outbreaks 3

  4. Slide 4: No Approved Norovirus Vaccines or Treatments Available

    No Approved Norovirus Vaccines or Treatments Available 1968-2025 1 Multiple vaccine clinical studies initiated since 2010 High norovirus genetic variation and drift: Challenge 2 10 genogroups & 49 genotypes Pan-viral protease inhibitor CDI-988 Solution 3 • Convenient oral regimen for both prevention

  5. Slide 5: Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals

    Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals Grow drug target Select drug Hit-to-lead Lead No treatment or vaccines available X-ray crystals binding pocket process optimization Direct-Acting Antiviral Drug Candidate (A) In-house screening: (B) Focus on highly conserved

  6. Slide 6: Roadmap For First Antiviral, CDI-988, For Acute and Chronic Norovirus Infection

    Roadmap For First Antiviral, CDI-988, For Acute and Chronic Norovirus Infection FDA Fast Track Designation Granted 04 Phase 1b: Norovirus Challenge Study Ongoing Phase 1 03 Favorable safety and tolerability Dose range: 100 – 1,200 mg 02 GLP Toxicology Favorable safety profile No-Observed-Adverse-Eff

  7. Slide 7: High Resolution X-ray Cocrystal Structures Confirm Broad-Spectrum Coverage

    High Resolution X-ray Cocrystal Structures Confirm Broad-Spectrum Coverage Structures of Norovirus Genogroups I and II, including GII.1, GII.2, GII.3 GII.4, GII.6 and GII.17 (1.1 – 2.3 Å) Norwalk (GI) Southampton (GI) Norovirus (GII.1) Norovirus (GII.2) Norovirus (GII.3) Norovirus (GII.3) Norovirus

  8. Slide 8: Promising PK/PD Property of CDI-988: Higher Exposure and Longer Half-Life in Intestine and Stomach

    Promising PK/PD Property of CDI-988: Significantly Higher Exposure and Longer Half-Life of Oral CDI-988 in Intestine and Stomach 100,000 ▪ GI-targeted activity was one of the Drug concentration (ng/mL) 10,000 Stomach norovirus lead selection criteria Stomach Small intestine 1,000 Small Intestine ▪ D

  9. Slide 9: Safety Assessment Using Human 3-D Small Intestinal Tissue System

    Safety Assessment Using Human 3-D Small Intestinal Tissue System (EpiIntestinalFT Model System) (A) TEER (Transepithelial Electrical 120 Resistance) Assay (B) MTT cell viability assay 120 Reference compound, 120.0 100 100 SN-38, causes GI 100.0 toxicity, causing % Viability (Relative to NC) % TEER (

  10. Slide 10: CDI-988 Shows Favorable Safety and Functional Profiles in Human Small Intestinal Tissue

    CDI-988 Shows Favorable Safety and Functional Profiles in Human Small Intestinal Tissue (A) TEER (Transepithelial Electrical Resistance) Assay (B) MTT cell viability assay SN-38 CDI-988 CDI-988 120 120.0 20 M 100 M 0.41 M 100 M 0.41 M 100 100.0 % Viability (Relative to NC) % TEER (Relative to N

  11. Slide 11: CDI-988 Shows No Gastrointestinal Toxicity in Human Small Intestine Organoid System

    CDI-988 Shows No Gastrointestinal Toxicity in Human Small Intestine Organoid System 20 M SN-38 No CDI-988 1 M CDI-988 100 M CDI-988 11 11

  12. Slide 12: In Vitro Efficacy of CDI-988 in Norovirus GII.4 Infected Human Intestinal Enteroids

    In Vitro Efficacy of CDI-988 in Norovirus GII.4 Infected 3-D Differentiated Human Intestinal Enteroids (HIEs) ▪ 2-log reduction in CDI-988-treated 3-D human intestinal enteroids HNoV GII.4 Replication in 3D-FI124 Human norovirus GII.4 isolates from stool ✱✱✱✱ 6 ✱✱✱✱ Mean Log viral genome copies per

  13. Slide 13: Phase 1 Study: CDI-988 Showed Favorable Safety and Tolerability

    Phase 1 Study: Oral Pan-viral Protease Inhibitor CDI-988 Showed Favorable Safety and Tolerability ▪ Single-center, randomized, double-blind, placebo-controlled ▪ Single-ascending dose (SAD) and Multiple-ascending dose (MAD) cohorts ▪ Healthy adult volunteers (18 – 55 years old) ▪ Each cohort compris

  14. Slide 14: Phase 1 Topline Safety Data Summary

    Phase 1 Topline Safety Data Summary ▪ Demonstrated favorable safety profile ▪ Well tolerated ▪ Major adverse effect: headache Single Ascending Dose Cohorts Multiple Ascending Dose Cohorts Overall treatment-emergent AE (TEAE) rate Overall treatment-emergent (TEAE) rate ▪ 28% (10/36) in CDI-988 cohort

  15. Slide 15: CDI-988 Phase 1b Norovirus Challenge Study Is Enrolling Participants

    CDI-988 Phase 1b Norovirus Challenge Study Is Enrolling Participants ▪ Norovirus GII.2 challenge study developed by our collaborators Emory and the University of North Carolina (UNC) ▪ Phase 1b study protocol (Sponsor: Cocrystal Pharma) has been approved by the FDA ▪ Current status: First dose with

  16. Slide 16: Norovirus Challenge Phase 1b Study Design

    Norovirus Challenge Phase 1b Study Design ▪ Design: Randomized, double-blind, placebo-controlled ▪ Number of participants: Up to 40, healthy adult volunteers (18-49 years old) ▪ Norovirus inoculum: GII.2 SMV ▪ Treatment: 1200 mg BID Day 1 – 5 ▪ Primary efficacy endpoint: Reduction in incidence of cl

  17. Slide 17: Acknowledgements

    Many thanks to our collaborators, norovirus experts, scientists, clinical investigators, adult volunteers, the staff at the study centers, the research organizations, and my colleagues at Cocrystal Pharma

Cocrystal Pharma — 2026 International Society For Antiviral Research (ICAR 2026) on 6ix